Chief Business Officer, Senior Vice President · ROCKET PHARMACEUTICALS, INC. (RCKT)

Raj Prabhakar

FY2022 is the first fiscal year CompBrief holds for Raj Prabhakar as a named executive officer of ROCKET PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,819,120

Salary $405,000Stock awards $399,993Bonus $193,600

4th of 7 named executive officers at Rocket Pharmaceuticals by FY2022 total.

7 named officers on file for ROCKET PHARMACEUTICALS, FY2022

Raj Prabhakar’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • RCKT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ROCKET PHARMACEUTICALS’s whole pay program stands against its peers

  • ROCKET PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RCKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A).

Free

Get Raj Prabhakar’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Raj Prabhakar compensation by year

ROCKET PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ROCKET PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$405,000
Bonus$193,600
Stock awards$399,993
Option awards$1,799,999
Non-equity incentive$0
Pension and deferred compensation$0
All other$20,527
Total$2,819,120

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ROCKET PHARMACEUTICALS, INC. DEF 14A filed April 28, 2023, accession 0001140361-23-021702, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ROCKET PHARMACEUTICALS, INC. filed document, accession 0001140361-23-021702. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU22,896$448,075—
Option2,498—$23.05
Option5,000—$17.98
Option500—$23.89
Option24,975—$62.32
Option145,093—$19.05

Per the Outstanding Equity Awards at Fiscal Year-End table in ROCKET PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

ROCKET PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Gaurav ShahChief Executive Officer$6,553,203
Kinnari PatelPresident and Chief Operating Officer$4,516,885
Mayo PujolsChief Technical Officer, Executive Vice President$3,149,702
Raj Prabhakar · this pageChief Business Officer, Senior Vice President$2,819,120
Jonathan SchwartzChief Medical and Gene Therapy Officer$2,532,457
John MilitelloPrincipal Accounting Officer and Interim Principal Financial Officer, Vice President$1,751,386
Carlos Garcia-ParadaFormer Chief Financial Officer and Principal Financial Officer$1,333,141

The full ROCKET PHARMACEUTICALS compensation record

free company brief

This page is one person within ROCKET PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ROCKET PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ROCKET PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Raj Prabhakar's compensation dossier · One-time report. No refunds.